Summary
Serum concentrations of cis (Z)-flupentixol have been estimated in three male human volunteers who received cis (Z)-flupentixol by intravenous infusion, flupentixol (cis (Z)/trans (E) mixture, 1:1) orally as single and repeated doses, and i. m. cis (Z)-flupentixol decanoate in Viscoleo®. The intravenous data show that cis (Z)-flupentixol followed a multicompartment model, but it was not possible to fit the data to a two or three compartment model. The concentration curves after oral administration indicated relatively slow absorption with a peak concentration at 3–6 h, except for one case with peak at 1 h. The variation in the dosage interval after one daily oral administration was relatively limited (1.7–3.0 times), which indicates that 24 h is a reasonable dosage interval. Biological half-lives were estimated in different ways and showed some intra-individual variation; the half-life was of medium length (19–39 h). The serum concentrations after intramuscular injection of cis (Z)-flupentixol decanoate clearly demonstrated a depot effect, with a maximal concentration at 3–5 days after injection. The descending part of the serum curves allowed an approximate estimation of half-life of 3–8 days. This was not the elimination half-life, but in all probability the half-life of release of drug from the oil depot which was the rate-limiting step. From the areas under the serum concentration curves the fraction of orally administered cis (Z)-flupentixol available to the organism was calculated to be 55% (range 48–60%). The loss of drug might have been due to imcomplete absorption, but it is more likely that cis (Z)-flupentixol underwent first-pass metabolism in the gut wall and the liver. As the tablets contained about 50% cis (Z)-flupentixol, while the depot preparation contained 74% cis (Z)-flupentixol, the pharmacokinetically equivalent doses are: 10 mg tablet daily corresponds to 25 mg depot weekly. Calculation of systemic clearance gave values of 0.44–0.49 l/min, and an apparent volume of distribution was 12.5–17.2 l/kg.
Similar content being viewed by others
References
Curry SH, Whelpton R, De Schepper PJ, Vranckx S, Schiff AA (1978) Plasma fluphenazine concentrations after injection of long-acting esters. Lancet 2: 1217–1218
Curry SH, Whelpton R, De Schepper PJ, Vranckx S, Schiff AA (1979) Kinetics of Fluphenazine after Fluphenazine Dihydrochloride, Enanthate and Decanoate Administration to Man. Br J Clin Pharmacol 7: 325–331
Johnstone EC, Crow TJ, Frith CD, Carney MWP, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1: 848–851
Jørgensen A, Hansen V, Dahl Larsen U, Rauf Khan A (1969) Metabolism, Distribution and Excretion of Flupentixol. Acta Pharmacol Toxicol 27: 301–313
Jørgensen A, Fredricson Overø K, Hansen V (1971) Metabolism, Distribution and Excretion of Flupentixol Decanoate in Dogs and Rats. Acta Pharmacol Toxicol 29: 339–358
Jørgensen A, Gottfries CG (1972) Pharmacokinetic Studies on Flupentixol and Flupentixol Decanoate in Man using Tritium Labelled Compounds. Psychopharmacologia 27: 1–10
Jørgensen A, Hansen V (1976) Pharmacokinetics of Amitriptyline Infused Intravenously in Man. Eur J Clin Pharmacol 10: 337–341
Jørgensen A (1978) A sensitive and specific radioimmunoassay for cis (Z)-flupentixol in human serum. Life Sci 23: 1533–1542
Jørgensen A, Fredricson Overø K (1980) Clopenthixol and flupentixol depot preparations in outpatient schizophrenics. III Serum levels. Acta Psychiatr Scand 61: Suppl 279, 41–54
Muusze RG, Visser-Van der Weel AJ, Van der, Verzijden R, Oei TT (1977) Fluorimetrische bepaling op de dunne laag van de blodkoncentratie van thioxanthenen (Sordinol® en Fluanxol®) na orale en intramusculaire (depot) toediening. Bulletin van de coördinatiecommissie biochemisch onderzoek van de psychiatrische instituten van de nationale ziekenhuisraad 10: 1–8
Møller Nielsen I, Pedersen V, Nymark M, Franck KF, Boeck V, Fjalland B, Christensen AV (1973) The Comparative Pharmacology of Flupentixol and some Reference Neuroleptics. Acta Pharmacol Toxicol 33: 353–362
Stauning JA, Kirk L, Jørgensen A (1979) Comparison of Serum Levels After Intramuscular Injections of 2% and 10% Cis (Z)-flupentixol Decanoate in Viscoleo® to Schizophrenic Patients. Psychopharmacology 65: 69–72
Wiles DH, Gelder MG (1979) Plasma Fluphenazine Levels by Radioimmunoassay in Schizophrenic Patients Treated with Depot Injections of Fluphenazine Decanoate. Br J Clin Pharmacol 8: 565–570
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Jørgensen, A. Pharmacokinetic studies in volunteers of intravenous and oral cis (Z)-flupentixol and intramuscular cis (Z)-flupentixol decanoate in viscoleo® . Eur J Clin Pharmacol 18, 355–360 (1980). https://doi.org/10.1007/BF00561395
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561395